Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5results about How to "Improve pathological condition" patented technology

Medicinal patch needle for preventing and treating allergic rhinitis as well as preparation method and application of medicinal patch needle

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a medicine patch needle for preventing and treating allergic rhinitis and a preparation method and application thereof. The medicine patch needle mainly comprises a traditional Chinese medicine composition and a medicine patch thumbtack needle, and the traditional Chinese medicine composition is prepared from, by weight, 30-60 parts of radix astragali, 15-30 parts of radix angelicae sinensis, 10-25 parts of radix saposhnikoviae, 10-30 parts of rhizoma atractylodis, 10-30 parts of rhizoma acori graminei, 5-15 parts of herba asari, 10-30 parts of rhizoma chuanxiong, 10-20 parts of radix angelicae and 1-5 parts of borneol. The medicine needle patch can be used for preventing and treating allergic rhinitis, mild and lasting acupuncture stimulation is achieved on the skin part of the acupoint, the medicine can rapidly enter the acupoint along with the needle hole, in other words, the acupoint achieves the effects of harmonizing qi and blood, relieving stuffy nose and removing pathogenic qi under the dual action of the acupuncture stimulation and the medicine, and the medicine needle patch has the remarkable preventing and treating effect on the allergic rhinitis.
Owner:SHANXI UNIV OF CHINESE MEDICINE

Chrysanthemum plant-derived traditional Chinese medicine monomer composition for treating diabetic retinopathy as well as preparation method and application thereof

The invention discloses a traditional Chinese medicine monomer composition derived from chrysanthemum plants and used for treating diabetic retinopathy as well as a preparation method and application of the traditional Chinese medicine monomer composition. The traditional Chinese medicine monomer composition prepared from the chrysanthemum plant as the raw material is high in safety, small in side effect and definite in component and is prepared according to a specific ratio, and pharmacodynamic experiments prove that compared with an ethanol extract, the traditional Chinese medicine monomer composition is more remarkable in curative effect on diabetic retinopathy, and the curative effect of the traditional Chinese medicine monomer composition on diabetic retinopathy is better than that of a traditional Chinese medicine composition on diabetic retinopathy. The composition can improve the pathological state of diabetic retinopathy from multiple targets and multiple ways, specifically can inhibit body mass increase caused by high glucose, reduce blood glucose level, improve retinal tissue structure damage, recover retinal tissue thickness, inhibit retinal cell apoptosis and inflammatory response, reduce the expression level of HIF-1alpha and VEGF protein in retinal tissue, and can be used for treating diabetic retinopathy. Scientific basis and technical support are provided for research and development of novel drugs for treating the diabetic retinopathy, and important clinical significance and market application prospects are achieved.
Owner:ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE

Lactococcus garviae LG3092 producing bacteriocin GarQ and efficiently antagonizing multi-drug resistant helicobacter pylori and application thereof

ActiveCN117660238BNo side effectsNo residual riskBinding siteHigh survival rate
This invention discloses a strain of *Lactococcus gasseri* LG3092 that produces the bacteriocin GarQ and effectively antagonizes multidrug-resistant *Helicobacter pylori*, and its applications. *Lactococcus gasseri* LG3092 was deposited at the Guangdong Provincial Microbial Culture Collection Center on October 30, 2023, with accession number GDMCC No: 63939. Studies have shown that LG3092 has the following beneficial effects: (1) it can produce the bacteriocin GarQ, effectively inhibiting the growth of *Helicobacter pylori* and other common pathogenic bacteria; (2) it has a high survival rate in the stomach, can colonize the stomach, and can compete with pathogenic bacteria for binding sites, effectively reducing the infection rate of *Helicobacter pylori* in the stomach; (3) it can improve the pathological state of the stomach and alleviate inflammation. Therefore, *Lactococcus gasseri* LG3092 has great application potential in the preparation of products for the prevention or treatment of *H. pylori*, especially multidrug-resistant *H. pylori* infection.
Owner:GUANGDONG INST OF MICROBIOLOGY GUANGDONG DETECTION CENT OF MICROBIOLOGY +1

A composition of isoliquiritigenin for improving depression and a preparation method thereof

PendingCN122272606Aimprove pathological conditionreduce degradationIsoliquiritigeninBiomedical technology
This invention belongs to the field of biomedical technology, specifically relating to an isoliquiritigenin composition for improving depression and its preparation method. The isoliquiritigenin composition for improving depression comprises the following raw materials in parts by weight: 22-40 parts isoliquiritigenin, 10-17 parts N-acetyl-D-glucosamine, and 15-20 parts β-lapaquinone. Isoliquiritigenin, N-acetyl-D-glucosamine, and β-lapaquinone constitute a multi-target synergistic isoliquiritigenin composition for improving depression. Experimental results show that by taking the isoliquiritigenin composition prepared according to this invention, it can systematically exert its effects and comprehensively improve the pathological state of depression, showing broad application prospects.
Owner:JILIN UNIVERSITY

Application of Sema3E inhibitor in preparation of medicine for preventing, delaying or treating COPD small airway fibrosis

PendingCN121944115APromote activationIncreased proliferationOrganic active ingredientsRespiratory disorderSmall airwaysCOPD
The invention belongs to the technical field of biological medicines, discloses an application of a Sema3E inhibitor in preparation of a medicine for preventing, delaying or treating COPD small airway fibrosis, and proposes that the Sema3E inhibitor can be used for treating, preventing or delaying the COPD small airway fibrosis for the first time. The Sema3E inhibitor plays a role by inhibiting the expression of Sema3E. The specific molecular mechanism is as follows: by inhibiting the expression of Sema3E, inhibiting the expression of Wnt5a / b, beta-Catenin, increasing the expression of p-beta-Catenin, inhibiting the activation of a Wnt / beta-Catenin pathway, and inhibiting the activation / proliferation / migration of small airway fibroblasts. Through the mechanism, the effect of preventing, delaying or treating the COPD is achieved, and a new drug intervention target, namely Sema3E, is provided for treatment of the COPD.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH